AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

This week, the department of pharmaceuticals (DoP) said the Indian arm of US firm AbbVie violated the newly amended Uniform Code for Pharmaceutical Marketing Practices. What did AbbVie do, and ...

Blue Cross Blue Shield of Michigan announced plans in November to drop coverage for Humira, a popular but costly auto-immune drug, in favor of a lower-cost alternative. Credit: Bloomberg Rising costs ...

AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending ...

Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic ...

A dose de-escalation program targeting Humira (adalimumab) and Stelara (ustekinumab) saved more than $86,000 per successful intervention, according to research findings presented today at the American ...

The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...